Paul Duic, M.D., is a Neuro-Oncologist. He specializes in the medical management of brain tumors and spine tumors, including central nervous system (CNS) tumors, gliomas, metastatic tumors, and CNS lymphoma.
Dr. Duic received his undergraduate degree, Bachelor of Sciences, in Biological Sciences, from Columbia University, New York, NY magna cum laude. He obtained his medical degree at NYU School of Medicine, New York, NY.
Dr. Duic completed a Residency in Emergency Medicine at Johns Hopkins University. He also completed a Surgical Internship and three years of Neurological Surgery Residency at UC Davis Medical Center, Sacramento, CA. He subsequently completed a Fellowship in Neuro-Oncology at the Neuro-Oncology Branch of the National Cancer Institute, National Institutes of Health (NIH.) He returned to the Neuro-Oncology Branch of NIH before joining Neurological Surgery, P.C.
Dr. Duic has also served as a Lieutenant Commander in the Medical Corps of the United States Naval Reserve.
Dr. Duic published "Central Nervous System Tumors" in the Bethesda Handbook of Clinical Oncology. He has several manuscripts in preparation, including: "Selective Glioma Targeting by a Recombinant Adeno-Associated Virus Type 5 Vector," and "Phase I Study of CC-8490, a Selective Estrogen Receptor Modulator, in Patients With Recurrent Malignant Gliomas and Progressive, Diffuse, Infi ltrating Gliomas." He is an experienced co-investigator on multiple clinical trials at NIH involving many novel molecularly targeted agents. He has delivered neurosurgical grand rounds and spoken on several other occasions regarding these clinical trials, such as "The Development of Enzastaurin for Malignant Gliomas."
"Eltrombopag for the Treatment of Radiation-Induced Thrombocytopenia in a Patient with a Glioblastoma"
Duic JP,Grewal J, McConie K, Staszewski H, Haas J, Kesari S. J Neurooncol 2011~ Aug 11.
"Trial of Talampanel, a Glutamate Receptor Inhibitor, for Adults With Recurrent Malignant Gliomas"
Iwamoto FM, Kreisl TN, Kim L, Duic JP, Butman JA, Albert PS, Fine HA. Phase 2. Cancer 2010~ Apr 1; 116(7):1776-82.
OmmayaCisternography with Delayed Radiotracer Activity Demonstrated in the Peritoneal Cavity"
Scalcione LR, Katz DS, Duic JP, Grewal J, Yung EY. In-111 DTPA.
ClinNucl Med. 2009~ Dec;34(12):955-7.
"A Phase I Trial of Enzastaurin in Patients with Recurrent Gliomas"
Kreisl TN, Kim L, Moore K, Duic JP, Kotliarova S, Walling J, Musib L, Thornton D, Albert PS, Fine HA. .
Clin Cancer Res ~ 2009 May 5
"A Phase II Trial of Single Agent Bevacizumab Followed by BevacizumabPlusIrinotecan at Tumor Progression in Patients with Recurrent Glioblastoma."
Kreisl TN, Kim L, Moore K, Duic JP,, Royce C, Stroud I, Garren N, Mackey M, Butman J, Albert PS.
JCO 2009 ~ Feb 10; 27(5): 740-5.
Duic JP, Grewal J, Kesari S.
Medlink Neurology 2009.
Grewal J,Duic JP, Kesari S.
Medlink Neurology 2009.
"A Phase I Trial of Lenalidomide in Patients With Recurrent Primary Central Nervous System Tumors."
Fine HA, Kim L, Albert PS, Duic JP, Ma H, Figg WD, Royce C.
Clinical Cancer Research~ 2007;13(23):7101-06.
"Central Nervous System Tumors"
Mansky P, Duic JP, Fine HA.
In Bethesda Handbook of Clinical Oncology. J. Abraham, C.J. Allegra, and James Gulley (eds), 2nd Edition, Lippincott Williams & Wilkins, In Press, 2004.
Interview video with Paul